Kết quả hóa xạ đồng thời ung thư phổi không tế bào nhỏ giai đoạn III bằng phác đồ paclitaxel–carboplatin tại bệnh viện Ung Bướu Hà Nội=Outcomes of concurrent chemoradiotherapy using the paclitaxel–carboplatin regimen in patients with stage III non-small cell lung cancer at Hanoi Oncology hospital

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Liên Bùi, Thị Vân Anh Dương, Lệ Quyên Nguyễn, Thị Thảo Nịnh, Văn Quân Phan

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.46010

Bộ sưu tập: Metadata

ID: 478100

Thêm vào giỏ

Mô tả đặc điểm lâm sàng, cận lâm sàng và đánh giá đáp ứng và tác dụng không mong muốn của phác đồ hóa xạ trị đồng thời với paclitaxel – carboplatin ở bênh nhân ung thư phổi không tế bào nhỏ giai đoạn III không mổ được. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả hồi cứu kết hợp tiến cứu tiến hành trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn III không mổ được, sử dụng hóa chất phác đồ paclitaxel – carboplatin kết hợp với xạ trị liều 60-66 Gy tại bệnh viện Ung Bướu Hà Nội từ 01/2021 đến 10/2023. Kết quả: Có tổng số 41 bệnh nhân tham gia nghiên cứu, tỷ lệ bệnh nhân nam: nữ là 2,4:1, tuổi trung bình của đối tượng là 61, có 30 (73,2%) bệnh nhân có chỉ số toàn trạng ECOG 0. Ho là triệu chứng lâm sàng khởi phát thường gặp nhất ở 18 (43,9%) bệnh nhân. Có 30 (73,2%) bệnh nhân có tiền sử hút thuốc lá hoặc thuốc lào. Ung thư biểu tuyến chiếm đa số với 24 (58,5%) bệnh nhân, 22 (53,7%) bệnh nhân ở giai đoạn IIIB. Đáp ứng toàn bộ là 27/41 (65,9%) bệnh nhân trong đó 2 (4,9%) bệnh nhân đạt đáp ứng hoàn toàn, trung vị thời gian sống thêm không bệnh tiến triển là 11 tháng, tỉ lệ sống thêm không bệnh 3 năm là 47,6%. Có 2 bệnh nhân viêm thực quản độ 3, 4 chiếm 4,8%
viêm phổi độ 3, 4 gặp ở 3 trường hợp chiếm 7,3%. Hạ bạch cầu đa nhân trung tính độ 3, độ 4 gặp ở 3 (7,3%) bệnh nhân. Kết luận: Phác đồ hóa xạ trị đồng thời kết hợp paclitaxel – carboplatin với xạ trị liều 60- 66Gy là phác đồ an toàn và hiệu quả với độc tính chấp nhận được.To describe the clinical and subclinical characteristics, and to evaluate the response and adverse events of concurrent chemoradiotherapy with paclitaxel – carboplatin in patients with stage III unresectable non-small cell lung cancer (NSCLC). Subjects and Methods: This retrospective and prospective descriptive study was conducted on patients with stage III unresectable NSCLC, who were treated with paclitaxel – carboplatin regimen chemotherapy in combination with radiotherapy at doses of 60-66Gy at Hanoi Oncology Hospital from January 2021 to October 2023. Results: Totally 41 eligible patients were enrolled, the male-female ratio was 2.4:1, and the average age was 61. Thirty patients (73.2%) had an ECOG performance status of 0. Cough was the most common initial clinical symptom, occurring in 18 patients (43.9%). A history of smoking was present in 30 (73.2%) patients. Adenocarcinoma was the predominant histological type, found in 24 patients (58.5%), while 22 patients (53.7%) were in stage IIIB. The overall response rate was observed in 27 out of 41 patients (65.9%), with 2 patients (4.9%) achieving a complete response. The median progression-free survival (PFS) was 11 months, and the 3-year PFS rate was 47.6%. Grade 3 and 4 esophagitis occurred in 2 patients (4.8%), and grade 3 and 4 pneumonitis was observed in 3 patients (7.3%). Grade 3 and 4 neutropenia occurred in 3 patients (7.3%). Conclusion: The concurrent chemoradiotherapy regimen combining paclitaxel – carboplatin with radiotherapy at doses of 60-66Gy is a safe and effective treatment with acceptable toxicity levels.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR